Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)
In a groundbreaking study conducted by a collaborative team including Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, their research "Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)" has been brought to light. Published in a reputable academic journal——Clinical Cancer Research (IF=11.5), the study emphasizes a significant advancement in the personalized treatment and prognosis assessment of patients with multiple myeloma, a field that continues to seek more precise and predictive diagnostic tools.